APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biomarker Clinical Phase Outsourcing Services

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biomarker Clinical Phase Outsourcing Services Market Analysis and Forecast 2026-2032

4 March 2026191 pages

Choose your research edition.

Industry ResearchBiomarker Clinical Phase Outsourcing Services Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Biomarker Clinical Phase Outsourcing Services Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Biomarker Clinical Phase Outsourcing Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biomarker Clinical Phase Outsourcing Services Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Biomarker Clinical Phase Outsourcing Services Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Biomarker Clinical Phase Outsourcing Services market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Biomarker Clinical Phase Outsourcing Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biomarker Clinical Phase Outsourcing Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biomarker Clinical Phase Outsourcing Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biomarker Clinical Phase Outsourcing Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Biomarker Clinical Phase Outsourcing Services include ICON plc, Fujirebio lnc, Charles River Laboratories International,Inc., Laboratory Corporation of America Holdings, Parexel lnternational Corporation, Proteome Sciences plc, Eurofins Scientific, Wuxi AppTec Co., Ltd. and NorthEast BioAnalytical Laboratories LLC., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biomarker Clinical Phase Outsourcing Services, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biomarker Clinical Phase Outsourcing Services, also provides the revenue of main regions and countries. Of the upcoming market potential for Biomarker Clinical Phase Outsourcing Services, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biomarker Clinical Phase Outsourcing Services revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biomarker Clinical Phase Outsourcing Services market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Biomarker Clinical Phase Outsourcing Services revenue, projected growth trends, production technology, application and end-user industry.

Biomarker Clinical Phase Outsourcing Services Segment by Company

ICON plc

Fujirebio lnc

Charles River Laboratories International,Inc.

Laboratory Corporation of America Holdings

Parexel lnternational Corporation

Proteome Sciences plc

Eurofins Scientific

Wuxi AppTec Co., Ltd.

NorthEast BioAnalytical Laboratories LLC.

Celerion, Inc.

GenScript ProBio Co.,Ltd.

Biomarker Clinical Phase Outsourcing Services Segment by Type

Predictive Biomarker

Prognostic Biomarker

Safety Biomarker

Surrogate Endpoints

Biomarker Clinical Phase Outsourcing Services Segment by Application

Pharmaceutical Companies

Biotechnology Companies

Others

Biomarker Clinical Phase Outsourcing Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biomarker Clinical Phase Outsourcing Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biomarker Clinical Phase Outsourcing Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biomarker Clinical Phase Outsourcing Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Biomarker Clinical Phase Outsourcing Services in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Biomarker Clinical Phase Outsourcing Services company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biomarker Clinical Phase Outsourcing Services revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Predictive Biomarker Major Player Table 3. Prognostic Biomarker Major Player Table 4. Safety Biomarker Major Player Table 5. Surrogate Endpoints Major Player Table 6. Global Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Pharmaceutical Companies Major Player Table 8. Biotechnology Companies Major Player Table 9. Others Major Player Table 10. Biomarker Clinical Phase Outsourcing Services Industry Trends Table 11. Biomarker Clinical Phase Outsourcing Services Industry Drivers Table 12. Biomarker Clinical Phase Outsourcing Services Industry Opportunities and Challenges Table 13. Biomarker Clinical Phase Outsourcing Services Industry Restraints Table 14. Global Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Biomarker Clinical Phase Outsourcing Services Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Biomarker Clinical Phase Outsourcing Services Market Share by Region (2021-2026) Table 17. Global Biomarker Clinical Phase Outsourcing Services Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Biomarker Clinical Phase Outsourcing Services Market Share by Region (2027-2032) Table 19. Global Biomarker Clinical Phase Outsourcing Services Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Players (2021-2026) Table 21. Global Biomarker Clinical Phase Outsourcing Services Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Biomarker Clinical Phase Outsourcing Services Key Players Headquarters & Area Served Table 23. Global Biomarker Clinical Phase Outsourcing Services Players, Product Type & Application Table 24. Global Biomarker Clinical Phase Outsourcing Services Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Biomarker Clinical Phase Outsourcing Services by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Biomarker Clinical Phase Outsourcing Services Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Type (2021-2026) Table 31. Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Type (2027-2032) Table 32. Global Biomarker Clinical Phase Outsourcing Services Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Application (2021-2026) Table 36. Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Application (2027-2032) Table 37. ICON plc Company Information Table 38. ICON plc Business Overview Table 39. ICON plc Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. ICON plc Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 41. ICON plc Recent Development Table 42. Fujirebio lnc Company Information Table 43. Fujirebio lnc Business Overview Table 44. Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 46. Fujirebio lnc Recent Development Table 47. Charles River Laboratories International,Inc. Company Information Table 48. Charles River Laboratories International,Inc. Business Overview Table 49. Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 51. Charles River Laboratories International,Inc. Recent Development Table 52. Laboratory Corporation of America Holdings Company Information Table 53. Laboratory Corporation of America Holdings Business Overview Table 54. Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 56. Laboratory Corporation of America Holdings Recent Development Table 57. Parexel lnternational Corporation Company Information Table 58. Parexel lnternational Corporation Business Overview Table 59. Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 61. Parexel lnternational Corporation Recent Development Table 62. Proteome Sciences plc Company Information Table 63. Proteome Sciences plc Business Overview Table 64. Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 66. Proteome Sciences plc Recent Development Table 67. Eurofins Scientific Company Information Table 68. Eurofins Scientific Business Overview Table 69. Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 71. Eurofins Scientific Recent Development Table 72. Wuxi AppTec Co., Ltd. Company Information Table 73. Wuxi AppTec Co., Ltd. Business Overview Table 74. Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 76. Wuxi AppTec Co., Ltd. Recent Development Table 77. NorthEast BioAnalytical Laboratories LLC. Company Information Table 78. NorthEast BioAnalytical Laboratories LLC. Business Overview Table 79. NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 81. NorthEast BioAnalytical Laboratories LLC. Recent Development Table 82. Celerion, Inc. Company Information Table 83. Celerion, Inc. Business Overview Table 84. Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 86. Celerion, Inc. Recent Development Table 87. GenScript ProBio Co.,Ltd. Company Information Table 88. GenScript ProBio Co.,Ltd. Business Overview Table 89. GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 91. GenScript ProBio Co.,Ltd. Recent Development Table 92. North America Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026) & (US$ Million) Table 93. North America Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032) & (US$ Million) Table 94. North America Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026) & (US$ Million) Table 95. North America Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032) & (US$ Million) Table 96. North America Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021-2026) & (US$ Million) Table 98. North America Biomarker Clinical Phase Outsourcing Services Revenue by Country (US$ Million) & (2027-2032) Table 99. Europe Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021-2026) & (US$ Million) Table 105. Europe Biomarker Clinical Phase Outsourcing Services Revenue by Country (US$ Million) & (2027-2032) Table 106. China Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026) & (US$ Million) Table 107. China Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032) & (US$ Million) Table 108. China Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026) & (US$ Million) Table 109. China Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026) & (US$ Million) Table 111. Asia Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032) & (US$ Million) Table 112. Asia Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026) & (US$ Million) Table 113. Asia Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Biomarker Clinical Phase Outsourcing Services Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia Biomarker Clinical Phase Outsourcing Services Revenue by Region (US$ Million) & (2021-2026) Table 116. Asia Biomarker Clinical Phase Outsourcing Services Revenue by Region (US$ Million) & (2027-2032) Table 117. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026) & (US$ Million) Table 118. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032) & (US$ Million) Table 119. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026) & (US$ Million) Table 120. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032) & (US$ Million) Table 121. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021-2026) & (US$ Million) Table 123. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Country (US$ Million) & (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Biomarker Clinical Phase Outsourcing Services Image Figure 2. Global Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biomarker Clinical Phase Outsourcing Services Market Size Share 2021 VS 2025 VS 2032 Figure 4. Predictive Biomarker Image Figure 5. Prognostic Biomarker Image Figure 6. Safety Biomarker Image Figure 7. Surrogate Endpoints Image Figure 8. Global Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Biomarker Clinical Phase Outsourcing Services Market Size Share 2021 VS 2025 VS 2032 Figure 10. Pharmaceutical Companies Image Figure 11. Biotechnology Companies Image Figure 12. Others Image Figure 13. Global Biomarker Clinical Phase Outsourcing Services Market Size (US$ Million) & (2021-2032) Figure 14. Global Biomarker Clinical Phase Outsourcing Services Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Biomarker Clinical Phase Outsourcing Services Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Biomarker Clinical Phase Outsourcing Services Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Type (2021-2032) Figure 21. Global Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Application (2021-2032) Figure 24. North America Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032) Figure 26. North America Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032) Figure 27. North America Biomarker Clinical Phase Outsourcing Services Revenue Share by Country (2021-2032) Figure 28. United States Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032) Figure 33. Europe Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032) Figure 34. Europe Biomarker Clinical Phase Outsourcing Services Revenue Share by Country (2021-2032) Figure 35. Germany Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032) Figure 45. China Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032) Figure 46. Asia Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032) Figure 48. Asia Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032) Figure 49. Asia Biomarker Clinical Phase Outsourcing Services Revenue Share by Region (2021-2032) Figure 50. Japan Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032) Figure 58. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032) Figure 59. SAMEA Biomarker Clinical Phase Outsourcing Services Revenue Share by Country (2021-2032) Figure 60. Brazil Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Biomarker Clinical Phase Outsourcing Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Predictive Biomarker
  • Prognostic Biomarker
  • Safety Biomarker
  • Surrogate Endpoints
Applications
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Others
Companies covered
  • ICON plc
  • Fujirebio lnc
  • Charles River Laboratories International,Inc.
  • Laboratory Corporation of America Holdings
  • Parexel lnternational Corporation
  • Proteome Sciences plc
  • Eurofins Scientific
  • Wuxi AppTec Co., Ltd.
  • NorthEast BioAnalytical Laboratories LLC.
  • Celerion, Inc.
  • GenScript ProBio Co.,Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biomarker Clinical Phase Outsourcing Services Market by Type
  3. 1.2.1 Global Biomarker Clinical Phase Outsourcing Services Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Predictive Biomarker
  5. 1.2.3 Prognostic Biomarker
  6. 1.2.4 Safety Biomarker
  7. 1.2.5 Surrogate Endpoints
  8. 1.3 Biomarker Clinical Phase Outsourcing Services Market by Application
  9. 1.3.1 Global Biomarker Clinical Phase Outsourcing Services Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Pharmaceutical Companies
  11. 1.3.3 Biotechnology Companies
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Biomarker Clinical Phase Outsourcing Services Market Dynamics
  1. 2.1 Biomarker Clinical Phase Outsourcing Services Industry Trends
  2. 2.2 Biomarker Clinical Phase Outsourcing Services Industry Drivers
  3. 2.3 Biomarker Clinical Phase Outsourcing Services Industry Opportunities and Challenges
  4. 2.4 Biomarker Clinical Phase Outsourcing Services Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Biomarker Clinical Phase Outsourcing Services Market Perspective (2021-2032)
  2. 3.2 Global Biomarker Clinical Phase Outsourcing Services Growth Trends by Region
  3. 3.2.1 Global Biomarker Clinical Phase Outsourcing Services Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biomarker Clinical Phase Outsourcing Services Market Size by Region (2021-2026)
  5. 3.2.3 Global Biomarker Clinical Phase Outsourcing Services Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Biomarker Clinical Phase Outsourcing Services Revenue by Players
  2. 4.1.1 Global Biomarker Clinical Phase Outsourcing Services Revenue by Players (2021-2026)
  3. 4.1.2 Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Biomarker Clinical Phase Outsourcing Services Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biomarker Clinical Phase Outsourcing Services Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Biomarker Clinical Phase Outsourcing Services Key Players Headquarters & Area Served
  7. 4.4 Global Biomarker Clinical Phase Outsourcing Services Players, Product Type & Application
  8. 4.5 Global Biomarker Clinical Phase Outsourcing Services Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Biomarker Clinical Phase Outsourcing Services Market CR5 and HHI
  11. 4.6.3 2025 Biomarker Clinical Phase Outsourcing Services Tier 1, Tier 2, and Tier 3
5 Biomarker Clinical Phase Outsourcing Services Market Size by Type
  1. 5.1 Global Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2032)
  3. 5.3 Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Type (2021-2032)
6 Biomarker Clinical Phase Outsourcing Services Market Size by Application
  1. 6.1 Global Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2032)
  3. 6.3 Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 ICON plc
  2. 7.1.1 ICON plc Company Information
  3. 7.1.2 ICON plc Business Overview
  4. 7.1.3 ICON plc Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  5. 7.1.4 ICON plc Biomarker Clinical Phase Outsourcing Services Product Portfolio
  6. 7.1.5 ICON plc Recent Developments
  7. 7.2 Fujirebio lnc
  8. 7.2.1 Fujirebio lnc Company Information
  9. 7.2.2 Fujirebio lnc Business Overview
  10. 7.2.3 Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Product Portfolio
  12. 7.2.5 Fujirebio lnc Recent Developments
  13. 7.3 Charles River Laboratories International,Inc.
  14. 7.3.1 Charles River Laboratories International,Inc. Company Information
  15. 7.3.2 Charles River Laboratories International,Inc. Business Overview
  16. 7.3.3 Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  18. 7.3.5 Charles River Laboratories International,Inc. Recent Developments
  19. 7.4 Laboratory Corporation of America Holdings
  20. 7.4.1 Laboratory Corporation of America Holdings Company Information
  21. 7.4.2 Laboratory Corporation of America Holdings Business Overview
  22. 7.4.3 Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Product Portfolio
  24. 7.4.5 Laboratory Corporation of America Holdings Recent Developments
  25. 7.5 Parexel lnternational Corporation
  26. 7.5.1 Parexel lnternational Corporation Company Information
  27. 7.5.2 Parexel lnternational Corporation Business Overview
  28. 7.5.3 Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Product Portfolio
  30. 7.5.5 Parexel lnternational Corporation Recent Developments
  31. 7.6 Proteome Sciences plc
  32. 7.6.1 Proteome Sciences plc Company Information
  33. 7.6.2 Proteome Sciences plc Business Overview
  34. 7.6.3 Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Product Portfolio
  36. 7.6.5 Proteome Sciences plc Recent Developments
  37. 7.7 Eurofins Scientific
  38. 7.7.1 Eurofins Scientific Company Information
  39. 7.7.2 Eurofins Scientific Business Overview
  40. 7.7.3 Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Product Portfolio
  42. 7.7.5 Eurofins Scientific Recent Developments
  43. 7.8 Wuxi AppTec Co., Ltd.
  44. 7.8.1 Wuxi AppTec Co., Ltd. Company Information
  45. 7.8.2 Wuxi AppTec Co., Ltd. Business Overview
  46. 7.8.3 Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  48. 7.8.5 Wuxi AppTec Co., Ltd. Recent Developments
  49. 7.9 NorthEast BioAnalytical Laboratories LLC.
  50. 7.9.1 NorthEast BioAnalytical Laboratories LLC. Company Information
  51. 7.9.2 NorthEast BioAnalytical Laboratories LLC. Business Overview
  52. 7.9.3 NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  53. 7.9.4 NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  54. 7.9.5 NorthEast BioAnalytical Laboratories LLC. Recent Developments
  55. 7.10 Celerion, Inc.
  56. 7.10.1 Celerion, Inc. Company Information
  57. 7.10.2 Celerion, Inc. Business Overview
  58. 7.10.3 Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  60. 7.10.5 Celerion, Inc. Recent Developments
  61. 7.11 GenScript ProBio Co.,Ltd.
  62. 7.11.1 GenScript ProBio Co.,Ltd. Company Information
  63. 7.11.2 GenScript ProBio Co.,Ltd. Business Overview
  64. 7.11.3 GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  65. 7.11.4 GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  66. 7.11.5 GenScript ProBio Co.,Ltd. Recent Developments
8 North America
  1. 8.1 North America Biomarker Clinical Phase Outsourcing Services Revenue (2021-2032)
  2. 8.2 North America Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2032)
  3. 8.2.1 North America Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026)
  4. 8.2.2 North America Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032)
  5. 8.3 North America Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032)
  6. 8.4 North America Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2032)
  7. 8.4.1 North America Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026)
  8. 8.4.2 North America Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032)
  9. 8.5 North America Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032)
  10. 8.6 North America Biomarker Clinical Phase Outsourcing Services Revenue by Country
  11. 8.6.1 North America Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021-2026)
  13. 8.6.3 North America Biomarker Clinical Phase Outsourcing Services Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Biomarker Clinical Phase Outsourcing Services Revenue (2021-2032)
  2. 9.2 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2032)
  3. 9.2.1 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026)
  4. 9.2.2 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032)
  5. 9.3 Europe Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032)
  6. 9.4 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2032)
  7. 9.4.1 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026)
  8. 9.4.2 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032)
  9. 9.5 Europe Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032)
  10. 9.6 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Country
  11. 9.6.1 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021-2026)
  13. 9.6.3 Europe Biomarker Clinical Phase Outsourcing Services Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Biomarker Clinical Phase Outsourcing Services Revenue (2021-2032)
  2. 10.2 China Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2032)
  3. 10.2.1 China Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026)
  4. 10.2.2 China Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032)
  5. 10.3 China Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032)
  6. 10.4 China Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2032)
  7. 10.4.1 China Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026)
  8. 10.4.2 China Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032)
  9. 10.5 China Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biomarker Clinical Phase Outsourcing Services Revenue (2021-2032)
  2. 11.2 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2032)
  3. 11.2.1 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026)
  4. 11.2.2 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032)
  5. 11.3 Asia Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032)
  6. 11.4 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2032)
  7. 11.4.1 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026)
  8. 11.4.2 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032)
  9. 11.5 Asia Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032)
  10. 11.6 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Country
  11. 11.6.1 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021-2026)
  13. 11.6.3 Asia Biomarker Clinical Phase Outsourcing Services Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue (2021-2032)
  2. 12.2 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Type (2027-2032)
  5. 12.3 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Application (2027-2032)
  9. 12.5 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Country
  11. 12.6.1 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Biomarker Clinical Phase Outsourcing Services Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst